PV-10 (Rose Bengal) Clinical Value Proposition: A blog post first authored March 13, 2012, and later revised April 18, 2012, May 28, 2012 and December 8, 2014.
|Click to enlarge.|
- Provectus Biopharmaceuticals: Worth of $150 per share, a blog post originally authored January 12, 2014. An updated post, Worth of $120 per share, authored May 14, 2014, reflected an increase in fully diluted shares outstanding.
- Getting to a Worth of $150 per share: Melanoma, a blog post authored January 19, 2014.
PV-10, and the Cancer Immunity Cycle: A blog post authored July 16, 2014 (click on the link to access the presentation). See below: An updated perspective on this may be found in Provectus' BioPharma Asia Convention presentation on March 23, 2016 entitled "Altering T cells and induced tumor-specific immunity via PV-10 ablation" (see the blog's Disclosure page on this topic).
Industry/Investor Conference Presentations: (see the blog's Disclosure page on this topic)
- Altering T cells and induced tumor-specific immunity via PV-10 ablation: March 2016 BioPharma Asia Convention
- Rose Bengal: A first-in-class halogenated xanthene with unique therapeutic properties for fighting cancer and inflammatory dermatoses: May 2016 CHINABIO Partnering Forum
- Rose Bengal: Small Molecule Ablative Immunotherapy